The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp194
THE GENETIC EPIDEMIOLOGY OF PANCREATIC CANCER: RECENT INNOVATIONS IN AN EVOLVING LANDSCAPE
Date
May 6, 2023
Explore related products in the following collection:
A translational symposium that focuses on the evolving role of artificial intelligence and machine learning in early detection of pancreatic cancer, genetic testing and novel molecular diagnostic bio-markers and recent advances in digital tools that can be applied to enhance early detection and improve care of high-risk individuals.
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…